CD19 and B-cell chronic lymphocytic leukemia: It can be estimated that, out of the approximately 100 CLL patients enrolled in anti-CD19 CAR T cell therapy to date, almost all were heavily pretreated patients who experienced disease relapse or who were refractory to conventional therapy regimens.